Neurocrine Biosciences, Inc.
NBIXNeurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
Drugs in Pipeline
20
Phase 3 Programs
8
Upcoming Catalysts
2
Next Catalyst
Jul 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
How NBIX's past catalysts played out
NBI-1065845
Major Depressive Disorder
NBI-98854
Tardive Dyskinesia
NBI-1117568
Schizophrenia
Valbenazine
Tardive Dyskinesia
Chronocort
Congenital Adrenal Hyperplasia
Crinecerfont
Congenital Adrenal Hyperplasia
Infacort®
Adrenal Insufficiency
Chronocort®
Congenital Adrenal Hyperplasia
TAK-831
Friedreich Ataxia
interleukin-4 PE38KDEL cytotoxin
Brain and Central Nervous System Tumors
NBI-827104
Epileptic Encephalopathy
Plenadren
Primary Adrenal Insufficiency
Cortef
Congenital Adrenal Hyperplasia
NBI-921352
SCN8A Developmental and Epileptic Encephalopathy Syndrome
NBI-74788
CAH - Congenital Adrenal Hyperplasia
NBI-1070770
Major Depressive Disorder
TAK-041
Stable Schizophrenia
NBI-5788
Multiple Sclerosis
Luvadaxistat
Schizophrenia
NBI-1065846
Anhedonia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NBI-1065845 | Phase 3 | Major Depressive Disorder | - | - |
NBI-98854 | Phase 3 | Tardive Dyskinesia | - | - |
NBI-1117568 | Phase 3 | Schizophrenia | - | - |
Valbenazine | Phase 3 | Tardive Dyskinesia | - | - |
Chronocort | Phase 3 | Congenital Adrenal Hyperplasia | - | - |
Crinecerfont | Phase 3 | Congenital Adrenal Hyperplasia | - | - |
Infacort® | Phase 3 | Adrenal Insufficiency | - | - |
Chronocort® | Phase 3 | Congenital Adrenal Hyperplasia | - | - |
TAK-831 | Phase 2 | Friedreich Ataxia | - | - |
interleukin-4 PE38KDEL cytotoxin | Phase 2 | Brain and Central Nervous System Tumors | - | - |
NBI-827104 | Phase 2 | Epileptic Encephalopathy | - | - |
Plenadren | Phase 2 | Primary Adrenal Insufficiency | - | - |
Cortef | Phase 2 | Congenital Adrenal Hyperplasia | - | - |
NBI-921352 | Phase 2 | SCN8A Developmental and Epileptic Encephalopathy Syndrome | - | - |
NBI-74788 | Phase 2 | CAH - Congenital Adrenal Hyperplasia | - | - |
NBI-1070770 | Phase 2 | Major Depressive Disorder | - | - |
TAK-041 | Phase 2 | Stable Schizophrenia | - | - |
NBI-5788 | Phase 2 | Multiple Sclerosis | - | - |
Luvadaxistat | Phase 2 | Schizophrenia | - | - |
NBI-1065846 | Phase 2 | Anhedonia | - | - |
obesity, metabolic disease
1 drug in this indication
Obesity and metabolic disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Neurocrine Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 20 drug candidates in Neurocrine Biosciences, Inc.'s (NBIX) pipeline across Phase 3, Phase 2. Its lead program is NBI-1065845 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Neurocrine Biosciences, Inc.'s next FDA catalyst?→
Neurocrine Biosciences, Inc.'s (NBIX) next tracked catalyst is a Phase 3 expected July 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NBIX biotech catalysts?→
Add NBIX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Neurocrine Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.